Janssen Amends its Agreement with Protagonist to Develop and Commercialize IL-23 Antagonists

 Janssen Amends its Agreement with Protagonist to Develop and Commercialize IL-23 Antagonists

Janssen Amends its Agreement with Protagonist to Develop and Commercialize IL-23 Antagonists

Shots:

  • Protagonist to receive ~ $900M as development & sales milestones along with $80M already received under the original agreement with royalty rates remain unchanged. Janssen will get right to continue research on IL-23 receptor antagonists developed under a collaboration for 3yrs. following the closing of the amended agreement
  • Janssen will lead all future studies beyond the currently ongoing studies with PTG-200, PN-232 and PN-235 and will be solely financially responsible for any studies. The company will deploy its capabilities & experience for further development of these assets
  • PTG-200 is currently in P-II study for CD while PN-232 and PN-235 are currently in P-I clinical development

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Protagonist

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post